



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

April 28, 2020

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)





Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/2 /2020-2021

April 28, 2020

NATCO's VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL

Hyderabad, India, April 28th, 2020

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce final approval of its 1st supplemental abbreviated new drug application (sANDA) product from the U.S. Food and Drug Administration (USFDA) filed from its new drug formulations facility in JNPC SEZ, Ramky Pharma City, Visakhapatnam (Vizag), Andhra Pradesh, India.

The sANDA, submitted as "Prior Approval Supplement," provides for NATCO's Vizag facility as an alternate site for manufacture of the approved drug product for the US market.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)

